Research programme: beta-amyloid fibrillogenesis inhibitors - Elan Pharmaceuticals/Neuralab

Drug Profile

Research programme: beta-amyloid fibrillogenesis inhibitors - Elan Pharmaceuticals/Neuralab

Alternative Names: beta-amyloid fibrillogenesis inhibitors research programme - Elan Pharmaceuticals/Neuralab; Research programme: amyloid-beta fibrillogenesis inhibitors - Elan Pharmaceuticals/Neuralab

Latest Information Update: 24 Jun 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Elan Corporation; Neuralab
  • Class Small molecules
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Alzheimer's disease

Most Recent Events

  • 23 Apr 2001 Preclinical development for Alzheimer's disease in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top